|Videos|January 24, 2022
SABCS 2021: Brain Metastases Updates in Breast Cancer
Focusing on datasets from the SABCS 2021 Virtual Meeting, panelists consider novel approaches to the management of brain metastases in breast cancer.
Advertisement
Data from the following clinical trials are discussed:
- PD4-02: Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis in HER2+ breast cancer: Results from TBCRC049, a phase 2 nonrandomized study
- PD4-04: Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB)
- P1-18-26: Intracranial efficacy of tucatinib, palbociclib, and letrozole combination in patients with HR+/HER2+ breast cancer and brain metastases
- P1-21-03: Efficacy of tyrosine kinase inhibitors (TKIs) in the treatment of patients with HER2+ breast cancer with or without brain metastases: a systematic review and meta-analysis
- OT1-13-01: HER2CLIMB-04: phase 2 trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases
Advertisement
Related to this article
T-DXd plus pertuzumab was approved in the European Union as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The sNDA is supported by VIKTORIA-1 Study 2 data showing that gedatolisib-based regimens approximately doubled median PFS vs alpelisib plus fulvestrant.
The European Commission approved sacituzumab govitecan plus pembrolizumab for treatment-naive, PD-L1-positive metastatic triple-negative breast cancer.
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Sara Nunnery, MD, MSCI, and Irene M. Kang, MD, discuss toxicity and monitoring considerations for the use of ADCs in metastatic TNBC.
ASCO’s ctDNA guidelines support testing for genetic alterations in select scenarios but do not endorse it for residual disease or recurrence monitoring.
Advertisement
Advertisement
Trending on OncLive
1
European Commission Approves T-DXd Plus Pertuzumab for First-Line HER2+ Metastatic Breast Cancer
2
Dr Huffman on the Mechanism of Action of INCB161734 in KRAS G12D–Mutated Metastatic Pancreatic Cancer
3
TP53 Status and Treatment Toxicity Burden Guide Sequencing in EGFR-Mutated NSCLC
4
FDA Grants Fast Track Designation to MT027 for Recurrent Glioblastoma
5